首页> 美国卫生研究院文献>Journal of the Canadian Association of Gastroenterology >A22 LIVER TYPE FATTY ACID BINDING PROTEIN (FABP1) LEVELS IMPROVE PERFORMANCE OF PROGNOSTIC MODELS IN ACETAMINOPHEN INDUCED ACUTE LIVER FAILURE
【2h】

A22 LIVER TYPE FATTY ACID BINDING PROTEIN (FABP1) LEVELS IMPROVE PERFORMANCE OF PROGNOSTIC MODELS IN ACETAMINOPHEN INDUCED ACUTE LIVER FAILURE

机译:A22肝型脂肪酸结合蛋白(FABP1)的水平提高了乙胺磷引起的急性肝功能衰竭预后模型的性能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAcetaminophen (APAP) - induced acute liver failure (ALF) is associated with significant mortality. To date, traditional prognostic scores (King’s College Criteria ~ KCC; Acute Liver Failure Study Group (ALFSG) prognostic index) lack discrimination in identifying patients with APAP-ALF who will die without liver transplant (LT), and those who will survive with medical management alone. Liver-type fatty acid binding protein (FABP1) is a 15 kDa cytoplasmic protein abundantly expressed in hepatocytes with potential prognostic value in APAP-ALF patients.
机译:背景对乙酰氨基酚(APAP)-诱发的急性肝衰竭(ALF)与明显的死亡率相关。迄今为止,传统的预后评分(King's College Criteria〜KCC;急性肝衰竭研究组(ALFSG)预后指数)缺乏辨别APAP-ALF患者的证据,这些患者无需肝移植就可以死亡(LT),并且可以通过药物生存独自管理。肝型脂肪酸结合蛋白(FABP1)是在肝细胞中大量表达的15 kDa细胞质蛋白,对APAP-ALF患者具有潜在的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号